ECH CENTER 1600/2900

PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Supplitute for form 1449A/PTO

靴FORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 09/867.693 **Application Number**

(use as many sheets as necessary)

Sheet of 3

00/00/1000	
May 31, 2001	
Cooper, et al.	
1646	
Unassigned	
003659.00009	
	May 31, 2001 Cooper, et al. 1646 Unassigned

			U.S. PATENT D	OCUMENTS	
Examiner		Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan
Initials *	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear
AV-		US-5,656,611	08 -12-1997	Kabanov, et al.	
			-		′
					-
			,		
·					

		FOREIGN I	PATENT DOCU	MENTS		
	0	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Examiner Cite No.1			Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶	
<u> </u>		EP 1031626	08-30-2001	Erbacher, et al.		
1		WO 9730731	08-28-1997	Lollo, et al.		
1	_	WO 9846274	10-28-1998	Burgess, et al.		
V						
			_	······································		

			y y 70	
Examiner Signature	Dow	Date Considered	117/03	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Duplicate

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE or respond to a collection of information unless a continuous collection of the collection

e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 09/867,693 May 31, 2001 Filing Date First Named Inventor Cooper, et al. Group Art Unit 1646 **Examiner Name** Unassigned Attorney Docket Number 003659.00009

(use as many sheets as necessary) of 3 Sheet 2

rm 1449A/PTO

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	8
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	600/2900
Dr		Aberle, et al., "The counterion influence on cationic lipid-mediated transfection of plasmid DNA", Biochemica et Biophysica Acta, 1996, pages 281-283, Elsevier Science B.V.	
		Allison, et al., "Mechanisms of Protection of Cationic Lipid-DNA Complexes During Lyophilization", Journal of Pharmaceutical Sciences, 2000, pages 682-691, vol. 89, no. 5, Wiley-Liss, Inc., & American Pharmaceutical Association.	
		Choi, et al., "Lactose-Poly (ethylene Glycol)-Grafted Poly-L-Lysine as Hepatoma Cell-Targeted Gene Carrier", Bioconjugate Chem., 1998, pages 708-718, vol. 9, Amerian Chemical Society.	
		Cortesi, et al., "Effecy of DNA Complexion and Freeze-Drying on the Physicochemical Characteristics of Cationic Liposomes", Antisense & Nucleic Drug Development, 2000, pages 205-215, vol. 10, Mary Ann Liebert, Inc.	
		Katayose, et al., "Remarkable Increase in Nuclease Resistance of Plasma DNA through Supramolecular Assembly with Poly (ethylene glycol)-Poly (L-lysine)", Journal of Pharmaceutical Sciences, 1998, vol. 87, no. 2, American Chemical Society and American Pharmaceutical Association.	
		Katayose, et al., "Water-Soluble Polyion Complex Associates of DNA and Poly (ethylene glycol)- Poly (L-lysine) Block Copolymer", Bioconjugate Chem., 1997, pages 702-707, American Chemical Society.	
		Kilcher, et al., "Influence of the DNA Complexation Medium on the Transfection Efficiency of Lipospermine/DNA Particles", Gene Therapy, 1998, pages 855-860, vol. 5, MacMillan Press LTD., Basingstoke, Great Britain.	
		Kwok, et al., "Strategies for Maintaining the Particle Size of Peptide DNA Condensates Following Freeze-Drying", International Journal of Pharmaceutics, 2000, pages 81-88, vol. 203, no. 1-2, Elsevier Science B.V.	
		Li, et al., "Lyophilization of Cationic Lipid-Protamine-DNA (LPD) Complexes", Journal of Pharmaceutical Sciences, 2000, pages 355-364, vol. 89, no. 3, Wiley-Liss, Inc., & American Pharmaceutical Association.	
/		Noel, et al., "High Compacted DNA – Polymer Complexes Via New Polynorbornene Polycationic Latexes With Acetate Counterion", SCISEARCH Database, 2000, pages 8980-8983, vol. 16, no. 23, American Chemical Society, Washington, D.C.	
/		Poxon, et al., "The Effect of Lyophilization on Plasmid DNA Activity", Pharmaceutical and Development Technology, 2000, pages 115-122, vol. 5, no. 1, Marcel Dekker, Inc.	

Examiner Signature	Dah	Date Considered	1/7/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PE	JCA
6,	BAIR E
(EB)	Linda Pa

PTO/SB/08B(10-01) Approved for use through 10/31/2002. OMB 0651-0031

	U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC
Paperwork Reduction Act of 1995, no persons a	re required to respond to a collection of information unless it contains a valid OMB control numb

Substitute	formal 1449A/PTO)	,		Complete if Known	
		Application Number	09/867,693			
	Filing Date	May 31, 2001				
	UPPLEMENTAL INFORMATION ISCLOSURE STATEMENT BY PPLICANT	First Named Inventor	Cooper, et al.	<u>Ç</u>		
APPLICANT		Group Art Unit	1646	-		
	(use as many she	ets as	necessary)	Examiner Name	Unassigned	Ĭ
Sheet	3	of	3	Attorney Docket Number	003659.00009	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	වු
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1600/2900
0		Toncheva, et al., "Novel vectors for gene delivery formed by self-assembly of DNA with poly (L-lysine) grafted with hydrophilic polymers", Biochemica et Biophysica Acta, 1998, pages 354-368, Elsevier Science B.V.	
W.		Vinogradov, et al., "Self-Assembly of Polyamine-Poly (ethylene glycol) Copolymers with Phosphorothicate Oligonucleotides", Bioconjugate Chem., 1998, pages 805-812, vol. 9, American Chemical Society.	

Examiner	ΩI		Date	119/102
Signature	Yall	\sim	Considered	11+102

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 09/867,693 Application Number Filing Date May 31, 2001 First Named Inventor Mark J. Cooper Group Art Unit NOT YET ASSIGNED **Examiner Name** NOT YET ASSIGNED Attorney Docket Number 03659.00009

(use as many sheets as necessary)

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
D^		ABERLE et al., The counterion influence on cationic lipid-mediated transfection of plasmid DNA, Biochimica et Biophysica Acta, 1996, 1299:281-283.	
1		VINOGRADOV et al., Self-Assembly of Polyamine-Poly(ethylene glycol) Copolymers with Phosphorothioate Oligonucleotides, Bioconjugate Chem., 1998, Vol. 9, No. 6, 805-812.	
		TONCHEVA et al., Novel vectors for gene delivery formed by self-assembly of DNA with poly_L-lysine) grafted with hydrophilic polymers, Biochimica et Biophysica Acta, 1998, 1380:354-368.	
		CHOI et al., Lactose-Poly(ethylene Glycol)-Grafted Poly-L-Lysine as Hepatoma Cell-Targeted Gene Carrier, Bioconjugate Chem., 1998, Vol. 9, No. 6, 708-718.	
		KATAYOSE et al., Water-Soluble Polyion Complex Associates of DNA and Poly(ethylene glycol)-Poly(L-lysine) Block Copolymer, Bioconjugate Chem., 1997, Vol. 8, No. 5, 702-707,	
		KATAYOSE et al., Remarkable Increasc in Nuclease Resistance of Plasmid DNA through Supramolecular Assembly with Poly(ethylene glycol)-Poly(L-lysine) Block Copolymer, Journal of Pharmaceutical Sciences, February 1998, Vol. 87, No. 2, 160-163.	
		KWOK et al., Strategies for maintaining the particle size of peptide DNA condensates following freeze-drying, International Journal of Pharmaceutics, 2000, Vol. 203, 81-88.	
		BEI et al., Lyophilization of Cationic Lipid-Protamine-DNA (LPD) Complexes, Journal of Pharmaceutical Sciences, March 2000, Vol. 89, No. 3, 355-364.	
		ALLISON et al., Mechanisms of Protection of Cationic Lipid-DNA Complexes During Lyophilization, Journal of Pharmaceutical Sciences, May 2000, Vol. 89, No. 5, 682-691.	
		CORTESI et al., Effect of DNA Complexation and Freeze-Drying on the Physicochemical Characteristics of Cationic Liposomes, Antisense & Nucleic Acid Drug Development, 2000, Vol. 10, 205-215.	
V		PAXON et al., The Effect of Lyophilization on Plasmid DNA Activity, Pharmaceutical Development and Technology, 2000, Vol. 5, Issue 1, 115-122.	

Examiner Signature	Dahn	Date Considered	1/7/03]
-----------------------	------	--------------------	--------	---

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

##3

PTO/SB/08A (08-00)

Approved for Userough 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 09/867,693

Filing Date May 31, 2001

First Named Inventor Mark J. Cooper

Group Art Unit NOT YET ASSIGNED

Examiner Name NOT YET ASSIGNED

Attorney Docket Number 03659.00009

H 33				U.S. PATENT DOCUM	MENTS	
Parminer (nitials		U.S. Patent Document Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Cite No. ¹					
₩		5,656,611		Kabanov et al.	08-12-1997	and the same of th
				-		

	FOREIGN PATENT DOCUMENTS							
Examiner Cite No.1	For	eign Patent De	ocument	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т ₆	
	Office ³	Number ⁴	Kind Code⁵ (<i>if known</i>)					
			<u> </u>					
			ļ					
			ļ					
		- 						
		 				 		
	<u> </u>							

(F	(1)		110100
Examiner Signature	())AA	Date Considered	117103
	0/100		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.